Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Colorectal Cancer

QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer
A Phase 1/2 Therapeutic, Open Label, Multi-Center Clinical Trial of NPC-1C, a Chimeric Monoclonal Antibody, in Adults With Recurrent, Locally Advanced Unresectable or Metastatic Pancreatic and Colorectal Cancer After Standard Therapy
Status: Enrolling
Updated:  8/3/2017
Moffitt Cancer Center
mi
from
Tampa, FL
QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer
A Phase 1/2 Therapeutic, Open Label, Multi-Center Clinical Trial of NPC-1C, a Chimeric Monoclonal Antibody, in Adults With Recurrent, Locally Advanced Unresectable or Metastatic Pancreatic and Colorectal Cancer After Standard Therapy
Status: Enrolling
Updated: 8/3/2017
Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer
A Phase 1/2 Therapeutic, Open Label, Multi-Center Clinical Trial of NPC-1C, a Chimeric Monoclonal Antibody, in Adults With Recurrent, Locally Advanced Unresectable or Metastatic Pancreatic and Colorectal Cancer After Standard Therapy
Status: Enrolling
Updated:  8/3/2017
The Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer
A Phase 1/2 Therapeutic, Open Label, Multi-Center Clinical Trial of NPC-1C, a Chimeric Monoclonal Antibody, in Adults With Recurrent, Locally Advanced Unresectable or Metastatic Pancreatic and Colorectal Cancer After Standard Therapy
Status: Enrolling
Updated: 8/3/2017
The Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer
A Phase 1/2 Therapeutic, Open Label, Multi-Center Clinical Trial of NPC-1C, a Chimeric Monoclonal Antibody, in Adults With Recurrent, Locally Advanced Unresectable or Metastatic Pancreatic and Colorectal Cancer After Standard Therapy
Status: Enrolling
Updated:  8/3/2017
Washington University in St. Louis
mi
from
Saint Louis, MO
QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer
A Phase 1/2 Therapeutic, Open Label, Multi-Center Clinical Trial of NPC-1C, a Chimeric Monoclonal Antibody, in Adults With Recurrent, Locally Advanced Unresectable or Metastatic Pancreatic and Colorectal Cancer After Standard Therapy
Status: Enrolling
Updated: 8/3/2017
Washington University in St. Louis
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated:  8/23/2017
Arizona Oncology Associates
mi
from
Tucson, AZ
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated: 8/23/2017
Arizona Oncology Associates
mi
from
Tucson, AZ
Click here to add this to my saved trials
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated:  8/23/2017
St. Jude Medical Center
mi
from
Fullerton, CA
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated: 8/23/2017
St. Jude Medical Center
mi
from
Fullerton, CA
Click here to add this to my saved trials
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated:  8/23/2017
Moores UCSD Cancer Center
mi
from
La Jolla, CA
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated: 8/23/2017
Moores UCSD Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated:  8/23/2017
Stanford Cancer Institute
mi
from
Palo Alto, CA
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated: 8/23/2017
Stanford Cancer Institute
mi
from
Palo Alto, CA
Click here to add this to my saved trials
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated:  8/23/2017
Innovative Clinical Research Institute, LLC
mi
from
Whittier, CA
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated: 8/23/2017
Innovative Clinical Research Institute, LLC
mi
from
Whittier, CA
Click here to add this to my saved trials
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated:  8/23/2017
Advanced Medical Specialists
mi
from
Miami, FL
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated: 8/23/2017
Advanced Medical Specialists
mi
from
Miami, FL
Click here to add this to my saved trials
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated:  8/23/2017
Lewis Hall Singletary Oncology Center
mi
from
Thomasville, GA
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated: 8/23/2017
Lewis Hall Singletary Oncology Center
mi
from
Thomasville, GA
Click here to add this to my saved trials
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated:  8/23/2017
Karmanos Cancer Institute
mi
from
Detroit, MI
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated: 8/23/2017
Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated:  8/23/2017
New Mexico Cancer Care Alliance
mi
from
Albuquerque, NM
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated: 8/23/2017
New Mexico Cancer Care Alliance
mi
from
Albuquerque, NM
Click here to add this to my saved trials
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated:  8/23/2017
Weill-Cornell Medical College
mi
from
New York, NY
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated: 8/23/2017
Weill-Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated:  8/23/2017
Oncology Hematology Care
mi
from
Cincinnati, OH
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated: 8/23/2017
Oncology Hematology Care
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated:  8/23/2017
Northwest Cancer Specialist, P.C
mi
from
Portland and Yualatin, OR
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated: 8/23/2017
Northwest Cancer Specialist, P.C
mi
from
Portland and Yualatin, OR
Click here to add this to my saved trials
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated:  8/23/2017
Albert Einstein Cancer Center
mi
from
Philadelphia, PA
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated: 8/23/2017
Albert Einstein Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated:  8/23/2017
Tennessee Oncology-Chattanooga
mi
from
Chattanooga, TN
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated: 8/23/2017
Tennessee Oncology-Chattanooga
mi
from
Chattanooga, TN
Click here to add this to my saved trials
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated:  8/23/2017
Tennessee Oncology PPLC SCRI
mi
from
Nashville, TN
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated: 8/23/2017
Tennessee Oncology PPLC SCRI
mi
from
Nashville, TN
Click here to add this to my saved trials
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated:  8/23/2017
Texas Oncology
mi
from
Bedford and Grapevine, TX
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated: 8/23/2017
Texas Oncology
mi
from
Bedford and Grapevine, TX
Click here to add this to my saved trials
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated:  8/23/2017
Texas Oncology - Dallas
mi
from
Dallas, TX
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated: 8/23/2017
Texas Oncology - Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated:  8/23/2017
Texas Oncology - Longview and Tyler
mi
from
Longview and Tyler, TX
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated: 8/23/2017
Texas Oncology - Longview and Tyler
mi
from
Longview and Tyler, TX
Click here to add this to my saved trials
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated:  8/23/2017
Cancer Care Center of South Texas-HOAST
mi
from
New Braunfels and San Antonio, TX
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated: 8/23/2017
Cancer Care Center of South Texas-HOAST
mi
from
New Braunfels and San Antonio, TX
Click here to add this to my saved trials
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated:  8/23/2017
Brooke Army Medical Center
mi
from
San Antonio, TX
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated: 8/23/2017
Brooke Army Medical Center
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated:  8/23/2017
Scott and White Healthcare
mi
from
Temple, TX
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated: 8/23/2017
Scott and White Healthcare
mi
from
Temple, TX
Click here to add this to my saved trials
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated:  8/23/2017
University of TX Health Science Center at Tyler
mi
from
Tyler, TX
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated: 8/23/2017
University of TX Health Science Center at Tyler
mi
from
Tyler, TX
Click here to add this to my saved trials
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated:  8/23/2017
Northwest Cancer Specialist
mi
from
Vancouver, WA
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated: 8/23/2017
Northwest Cancer Specialist
mi
from
Vancouver, WA
Click here to add this to my saved trials
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated:  8/23/2017
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated: 8/23/2017
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated:  8/23/2017
USC/Norris Comprehensive Cancer Center and LAC/USC Medical Center
mi
from
Los Angeles, CA
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated: 8/23/2017
USC/Norris Comprehensive Cancer Center and LAC/USC Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated:  8/23/2017
Rocky Mountain Cancer Centers
mi
from
Multiple Locations, CO
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated: 8/23/2017
Rocky Mountain Cancer Centers
mi
from
Multiple Locations, CO
Click here to add this to my saved trials
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated:  8/23/2017
Montefiore Medical Center
mi
from
The Bronx, NY
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated: 8/23/2017
Montefiore Medical Center
mi
from
The Bronx, NY
Click here to add this to my saved trials
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated:  8/23/2017
Oncology Hematology Consultants PA
mi
from
Fort Worth, TX
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated: 8/23/2017
Oncology Hematology Consultants PA
mi
from
Fort Worth, TX
Click here to add this to my saved trials
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated:  8/23/2017
Texas Oncology - Forth Worth
mi
from
Fort Worth, TX
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated: 8/23/2017
Texas Oncology - Forth Worth
mi
from
Fort Worth, TX
Click here to add this to my saved trials
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated:  8/23/2017
Virginia Oncology Associates
mi
from
Multiple Locations, VA
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated: 8/23/2017
Virginia Oncology Associates
mi
from
Multiple Locations, VA
Click here to add this to my saved trials
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated:  8/23/2017
Royal North Shore Hospital
mi
from
St Leonards,
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
Status: Enrolling
Updated: 8/23/2017
Royal North Shore Hospital
mi
from
St Leonards,
Click here to add this to my saved trials
Genotype-directed Neoadjuvant Chemoradiation for Rectal Carcinoma
Genotype-directed Neoadjuvant Chemoradiation for Rectal Carcinoma
Status: Enrolling
Updated:  9/7/2017
Washington University School of Medicine
mi
from
Saint Louis, MO
Genotype-directed Neoadjuvant Chemoradiation for Rectal Carcinoma
Genotype-directed Neoadjuvant Chemoradiation for Rectal Carcinoma
Status: Enrolling
Updated: 9/7/2017
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Phase I Study of KRN330 Monoclonal Antibody in Patients With Colorectal Cancer
Phase I Study of KRN330 Monoclonal Antibody in Patients With Colorectal Cancer
Status: Enrolling
Updated:  9/19/2017
Sarah Cannon Research Institute
mi
from
Nashville, TN
Phase I Study of KRN330 Monoclonal Antibody in Patients With Colorectal Cancer
Phase I Study of KRN330 Monoclonal Antibody in Patients With Colorectal Cancer
Status: Enrolling
Updated: 9/19/2017
Sarah Cannon Research Institute
mi
from
Nashville, TN
Click here to add this to my saved trials
Phase I Study of KRN330 Monoclonal Antibody in Patients With Colorectal Cancer
Phase I Study of KRN330 Monoclonal Antibody in Patients With Colorectal Cancer
Status: Enrolling
Updated:  9/19/2017
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Phase I Study of KRN330 Monoclonal Antibody in Patients With Colorectal Cancer
Phase I Study of KRN330 Monoclonal Antibody in Patients With Colorectal Cancer
Status: Enrolling
Updated: 9/19/2017
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Colorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo‑Controlled Phase-III STudy
A Randomized, Double-blind, Placebo-controlled Phase-III Study of Adjuvant Regorafenib Versus Placebo for Patients With Stage IV Colorectal Cancer After Curative Treatment of Liver Metastases
Status: Enrolling
Updated:  9/20/2017
Clinical Research Facility
mi
from
Laguna Hills, CA
Colorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo‑Controlled Phase-III STudy
A Randomized, Double-blind, Placebo-controlled Phase-III Study of Adjuvant Regorafenib Versus Placebo for Patients With Stage IV Colorectal Cancer After Curative Treatment of Liver Metastases
Status: Enrolling
Updated: 9/20/2017
Clinical Research Facility
mi
from
Laguna Hills, CA
Click here to add this to my saved trials
Colorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo‑Controlled Phase-III STudy
A Randomized, Double-blind, Placebo-controlled Phase-III Study of Adjuvant Regorafenib Versus Placebo for Patients With Stage IV Colorectal Cancer After Curative Treatment of Liver Metastases
Status: Enrolling
Updated:  9/20/2017
Clinical Research Facility
mi
from
Los Angeles, CA
Colorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo‑Controlled Phase-III STudy
A Randomized, Double-blind, Placebo-controlled Phase-III Study of Adjuvant Regorafenib Versus Placebo for Patients With Stage IV Colorectal Cancer After Curative Treatment of Liver Metastases
Status: Enrolling
Updated: 9/20/2017
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Colorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo‑Controlled Phase-III STudy
A Randomized, Double-blind, Placebo-controlled Phase-III Study of Adjuvant Regorafenib Versus Placebo for Patients With Stage IV Colorectal Cancer After Curative Treatment of Liver Metastases
Status: Enrolling
Updated:  9/20/2017
Clinical Research Facility
mi
from
Los Angeles, CA
Colorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo‑Controlled Phase-III STudy
A Randomized, Double-blind, Placebo-controlled Phase-III Study of Adjuvant Regorafenib Versus Placebo for Patients With Stage IV Colorectal Cancer After Curative Treatment of Liver Metastases
Status: Enrolling
Updated: 9/20/2017
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Colorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo‑Controlled Phase-III STudy
A Randomized, Double-blind, Placebo-controlled Phase-III Study of Adjuvant Regorafenib Versus Placebo for Patients With Stage IV Colorectal Cancer After Curative Treatment of Liver Metastases
Status: Enrolling
Updated:  9/20/2017
Clinical Research Facility
mi
from
Los Angeles, CA
Colorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo‑Controlled Phase-III STudy
A Randomized, Double-blind, Placebo-controlled Phase-III Study of Adjuvant Regorafenib Versus Placebo for Patients With Stage IV Colorectal Cancer After Curative Treatment of Liver Metastases
Status: Enrolling
Updated: 9/20/2017
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Colorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo‑Controlled Phase-III STudy
A Randomized, Double-blind, Placebo-controlled Phase-III Study of Adjuvant Regorafenib Versus Placebo for Patients With Stage IV Colorectal Cancer After Curative Treatment of Liver Metastases
Status: Enrolling
Updated:  9/20/2017
Clinical Research Facility
mi
from
New Haven, CT
Colorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo‑Controlled Phase-III STudy
A Randomized, Double-blind, Placebo-controlled Phase-III Study of Adjuvant Regorafenib Versus Placebo for Patients With Stage IV Colorectal Cancer After Curative Treatment of Liver Metastases
Status: Enrolling
Updated: 9/20/2017
Clinical Research Facility
mi
from
New Haven, CT
Click here to add this to my saved trials
Colorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo‑Controlled Phase-III STudy
A Randomized, Double-blind, Placebo-controlled Phase-III Study of Adjuvant Regorafenib Versus Placebo for Patients With Stage IV Colorectal Cancer After Curative Treatment of Liver Metastases
Status: Enrolling
Updated:  9/20/2017
Clinical Research Facility
mi
from
New Orleans, LA
Colorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo‑Controlled Phase-III STudy
A Randomized, Double-blind, Placebo-controlled Phase-III Study of Adjuvant Regorafenib Versus Placebo for Patients With Stage IV Colorectal Cancer After Curative Treatment of Liver Metastases
Status: Enrolling
Updated: 9/20/2017
Clinical Research Facility
mi
from
New Orleans, LA
Click here to add this to my saved trials
Colorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo‑Controlled Phase-III STudy
A Randomized, Double-blind, Placebo-controlled Phase-III Study of Adjuvant Regorafenib Versus Placebo for Patients With Stage IV Colorectal Cancer After Curative Treatment of Liver Metastases
Status: Enrolling
Updated:  9/20/2017
Clinical Research Facility
mi
from
Baltimore, MD
Colorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo‑Controlled Phase-III STudy
A Randomized, Double-blind, Placebo-controlled Phase-III Study of Adjuvant Regorafenib Versus Placebo for Patients With Stage IV Colorectal Cancer After Curative Treatment of Liver Metastases
Status: Enrolling
Updated: 9/20/2017
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Colorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo‑Controlled Phase-III STudy
A Randomized, Double-blind, Placebo-controlled Phase-III Study of Adjuvant Regorafenib Versus Placebo for Patients With Stage IV Colorectal Cancer After Curative Treatment of Liver Metastases
Status: Enrolling
Updated:  9/20/2017
Clinical Research Facility
mi
from
Detroit, MI
Colorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo‑Controlled Phase-III STudy
A Randomized, Double-blind, Placebo-controlled Phase-III Study of Adjuvant Regorafenib Versus Placebo for Patients With Stage IV Colorectal Cancer After Curative Treatment of Liver Metastases
Status: Enrolling
Updated: 9/20/2017
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
Colorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo‑Controlled Phase-III STudy
A Randomized, Double-blind, Placebo-controlled Phase-III Study of Adjuvant Regorafenib Versus Placebo for Patients With Stage IV Colorectal Cancer After Curative Treatment of Liver Metastases
Status: Enrolling
Updated:  9/20/2017
Clinical Research Facility
mi
from
Rochester, MN
Colorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo‑Controlled Phase-III STudy
A Randomized, Double-blind, Placebo-controlled Phase-III Study of Adjuvant Regorafenib Versus Placebo for Patients With Stage IV Colorectal Cancer After Curative Treatment of Liver Metastases
Status: Enrolling
Updated: 9/20/2017
Clinical Research Facility
mi
from
Rochester, MN
Click here to add this to my saved trials
Colorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo‑Controlled Phase-III STudy
A Randomized, Double-blind, Placebo-controlled Phase-III Study of Adjuvant Regorafenib Versus Placebo for Patients With Stage IV Colorectal Cancer After Curative Treatment of Liver Metastases
Status: Enrolling
Updated:  9/20/2017
Clinical Research Facility
mi
from
Omaha, NE
Colorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo‑Controlled Phase-III STudy
A Randomized, Double-blind, Placebo-controlled Phase-III Study of Adjuvant Regorafenib Versus Placebo for Patients With Stage IV Colorectal Cancer After Curative Treatment of Liver Metastases
Status: Enrolling
Updated: 9/20/2017
Clinical Research Facility
mi
from
Omaha, NE
Click here to add this to my saved trials
Colorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo‑Controlled Phase-III STudy
A Randomized, Double-blind, Placebo-controlled Phase-III Study of Adjuvant Regorafenib Versus Placebo for Patients With Stage IV Colorectal Cancer After Curative Treatment of Liver Metastases
Status: Enrolling
Updated:  9/20/2017
Clinical Research Facility
mi
from
New Brunswick, NJ
Colorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo‑Controlled Phase-III STudy
A Randomized, Double-blind, Placebo-controlled Phase-III Study of Adjuvant Regorafenib Versus Placebo for Patients With Stage IV Colorectal Cancer After Curative Treatment of Liver Metastases
Status: Enrolling
Updated: 9/20/2017
Clinical Research Facility
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Colorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo‑Controlled Phase-III STudy
A Randomized, Double-blind, Placebo-controlled Phase-III Study of Adjuvant Regorafenib Versus Placebo for Patients With Stage IV Colorectal Cancer After Curative Treatment of Liver Metastases
Status: Enrolling
Updated:  9/20/2017
Clinical Research Facility
mi
from
Buffalo, NY
Colorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo‑Controlled Phase-III STudy
A Randomized, Double-blind, Placebo-controlled Phase-III Study of Adjuvant Regorafenib Versus Placebo for Patients With Stage IV Colorectal Cancer After Curative Treatment of Liver Metastases
Status: Enrolling
Updated: 9/20/2017
Clinical Research Facility
mi
from
Buffalo, NY
Click here to add this to my saved trials
Colorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo‑Controlled Phase-III STudy
A Randomized, Double-blind, Placebo-controlled Phase-III Study of Adjuvant Regorafenib Versus Placebo for Patients With Stage IV Colorectal Cancer After Curative Treatment of Liver Metastases
Status: Enrolling
Updated:  9/20/2017
Clinical Research Facility
mi
from
New York, NY
Colorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo‑Controlled Phase-III STudy
A Randomized, Double-blind, Placebo-controlled Phase-III Study of Adjuvant Regorafenib Versus Placebo for Patients With Stage IV Colorectal Cancer After Curative Treatment of Liver Metastases
Status: Enrolling
Updated: 9/20/2017
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials